Skip to main content
    K

    Kalaris Therapeutics, Inc. (KLRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.19
    +0.06 (+2.82%)

    Market Cap: $53.09M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    77%(20/26)
    Avg Surprise
    -212.01%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.52
    Range$-0.57 - $-0.40
    8 analysts
    EPS Revisions
    4
    0
    7d
    4
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.52+0.2%
    60d ago$-0.52+0.2%
    30d ago$-0.52+1.0%
    7d ago$-0.52+1.0%
    Current$-0.52
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.47
    Range$-0.55 - $-0.32
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.47---
    Sep 26EST
    		-$-0.52---
    Jun 26
    Reported Aug 11
    		$-0.48$-0.50+4.00%Beat+21.3%
    Mar 26
    Reported May 12
    		$-0.46$-0.52+11.54%Beat+81.7%
    Dec 25
    Reported Mar 17
    		$-0.44$-0.55+20.00%Beat+86.6%
    Sep 25
    Reported Nov 12
    		$-0.64$-0.61-4.92%Miss+22.2%
    Jun 25
    Reported Aug 13
    		$-0.61$-0.52-17.31%Miss-1120.0%
    Mar 25
    Reported May 14
    		$-2.52$-0.77-227.27%Miss-869.2%
    Dec 24
    Reported Mar 7
    		$-3.28$-0.12-2633.33%Miss-530.8%
    Sep 24
    Reported Nov 12
    		$-0.82$-0.10-765.58%Miss-110.8%
    Jun 24
    Reported Aug 1
    		$-0.05$-0.05+0.00%Beat+89.6%
    Mar 24
    Reported May 2
    		$-0.26$-0.26+0.00%Beat+40.9%
    Dec 23
    Reported Feb 8
    		$-0.52$-0.52+0.00%Beat-62.5%
    Sep 23
    Reported Nov 2
    		$-0.39$-0.39+0.00%Beat+22.0%
    Jun 23
    Reported Aug 3
    		$-0.48$-0.48+0.00%Beat+30.4%
    Mar 23
    Reported Jun 29
    		$-0.44$-0.47+6.38%Beat+36.2%
    Dec 22
    Reported Mar 30
    		$-0.32$-0.32+0.00%Beat+65.2%
    Sep 22
    Reported Nov 3
    		$-0.50$-0.50+0.00%Beat+30.6%
    Jun 22
    Reported Aug 4
    		$-0.69$-0.69+0.00%Beat-15.0%
    Mar 22
    Reported Jun 29
    		$-0.69$-0.69+0.00%Beat-38.0%
    Dec 21
    Reported Mar 30
    		$-0.92$-0.92+0.00%Beat-124.4%
    Sep 21
    Reported Nov 5
    		$-0.72$-0.72+0.00%Beat-24.1%
    Jun 21
    Reported Aug 6
    		$-0.60$-0.60+0.00%Beat-76.5%
    Mar 21
    Reported Jun 29
    		$-0.50$-0.50+0.00%Beat+88.1%
    Dec 20
    Reported Mar 30
    		$-0.41$-0.44+6.82%Beat-
    Sep 20
    Reported Nov 10
    		$-0.58$-0.58+0.00%Beat-
    Jun 20
    Reported Jul 6
    		$-0.34N/A+92.33%Beat-
    Mar 20
    Reported Jun 29
    		$-4.21$-0.20-2005.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.08EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-79.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio10.98xQuick Ratio10.98x
    Trading Statistics
    BetaN/AAvg Volume81.75K
    52-Week High$11.8852-Week Low$2.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.44
    SMA 20$2.73
    SMA 50$3.40
    SMA 200$5.78
    EMA 10$2.42
    EMA 20$2.69
    EMA 50$3.24
    EMA 200$4.75

    MACD

    Line: -0.35Signal: -0.31Hist: -0.03

    ADX

    ADX: 51.8+DI: 4.9-DI: 33.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$2.78

    Bollinger Bands

    Upper Band$3.46
    Lower Band$2.01
    %B Position5293%(Upper)
    Band Width0.12

    RSI (14-Day)

    Oversold
    21.1

    Momentum Oscillators

    Stoch %K5.2
    Stoch %D3.7
    Williams %R-89.7
    ROC (10d)-23.2%
    Momentum-0.66
    CCI (20d)-131.9
    MFI (14d)10.9

    Volatility Measures

    ATR (14d)$0.19(8.8%)
    StdDev (20d)0.36
    Hist Vol48.7%(High)

    Volume Flow

    VWAP$2.17
    OBV461.0K
    AD Line-19.0M
    CMF (20d)-0.052

    Volume Metrics

    Avg Vol (20d)84.7K
    Vol Ratio0.7x
    VWMA (20d)$2.74

    Pivot Points

    R3$2.32
    R2$2.28
    R1$2.20
    Pivot Point$2.16
    S1$2.08
    S2$2.04
    S3$1.96

    Advanced Oscillators

    TSI-56.49
    Ultimate Osc36.6
    KST-299.43

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$10,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$-10,000$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$12.39M$11.83M$10.80M$12.74M$12.26M$10.35M$7.13M$37.85M$4.19M$2.56M$62.41M$46.96M
    R&D$9.02M$7.57M$7.16M$9.13M$8.44M$6.03M$3.85M$36.02M$3.21M$1.96M$33.37M$34.16M
    SG&A$3.37M$4.26M$3.64M$3.62M$3.82M$4.32M$3.28M$1.83M$976,000$602,000$10.46M$12.80M
    Operating Income$-12,386,000$-11,833,000$-10,801,000$-12,741,000$-12,256,000$-10,354,000$-7,133,000$-37,849,000$-4,187,000$-2,563,000$-62,405,000$-46,961,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$1.37M$1.52M
    Interest Expense$0$0$0$0$0$0$1.31M$815,000$499,000$78,000$0$0
    Income Before Tax$-11,515,000$-10,856,000$-9,998,000$-11,894,000$-11,350,000$-10,161,000$-22,026,000$-38,084,000$-5,650,000$-3,407,000$-59,822,000$-44,272,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-11,515,000$-10,856,000$-9,998,000$-11,894,000$-11,350,000$-10,196,000$-22,026,000$-38,084,000$-5,650,000$-3,407,000$-59,696,000$-44,272,000
    EBITDA$-11,619,000$-11,066,000$-10,304,000$-11,894,000$-11,350,000$-10,161,000$-20,717,000$-37,269,000$-5,151,000$-3,329,000$-62,264,000$-46,941,000
    EBIT$-11,515,000$-10,856,000$-9,998,000$-11,894,000$-11,350,000$-10,161,000$-20,717,000$-37,269,000$-5,151,000$-3,329,000$-61,193,000$-45,794,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KLRS

    News

    Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ

    This page provides live stock quotes and charts for Kalaris Therapeutics Inc. (KLRS). It shows the current stock price, recent performance...

    timothysykes.com•9/18/26•Neutral

    Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

    Kalaris Therapeutics, Inc. (Nasdaq: KLRS), a clinical-stage biopharmaceutical company, announced that its management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference....

    Investing News Network•8/31/26•Somewhat-Bullish

    Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

    Kalaris Therapeutics, Inc. announced that its management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15...

    The Manila Times•8/31/26•Somewhat-Bullish

    Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program

    Kalaris Therapeutics announced its Q2 2026 financial results, reporting $93.5 million in cash, cash equivalents, and marketable securities...

    VisionMonday.com•8/13/26•Neutral

    Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary

    Kalaris Therapeutics, Inc. reported a net loss of $(11.5M) for 2Q 2026, which was essentially flat compared to the previous year, while diluted loss per share improved to $(0.48). The company has no product revenue...

    TradingView•8/12/26•Neutral

    KLRS Valuation and Fair Value

    P/E
    -1.1x
    P/B
    0.9x
    See GNG's fair value

    KLRS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -79.9%

    KLRS Competitors

    CompanyTicker
    DarioHealth CorpDRIO
    Inspira Technologies Oxy BHN LtdIINN
    Kezar Life Sciences IncKZR
    Mink Therapeutics IncINKT
    Fractyl Health, Inc. Common StockGUTS
    Alterity Therapeutics LtdATHE
    Gossamer Bio IncGOSS
    Myomo IncMYO

    Sector: Healthcare

    KLRS Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    2
    Buy
    5
    Hold
    1
    Sell
    0
    Strong Sell
    0

    KLRS Bull Case vs Bear Case

    Bull case

    • 87.5% of KLRS's analyst ratings are Buy or Strong Buy.

    Bear case

    • KLRS beat EPS estimates in 37.5% of its last 8 reported quarters.

    KLRS Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -451.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.52
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 2 down

    Frequently Asked Questions About KLRS

    Does KLRS pay dividends?

    Kalaris Therapeutics, Inc. (KLRS) does not currently pay a regular dividend.

    What is KLRS's market cap?

    Kalaris Therapeutics, Inc. (KLRS) has a market capitalization of $53.09M with a current stock price of $2.19.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In